IP Library Granted Patent US 9,682,128
Granted Patent B2
US 9,682,128 · App. 14/741,883 · Granted Jun 20, 2017

Hypotonic aqueous composition with reduced chloride content, with or without phospholipids

Inventor: Michael Tchirikov (Halle, DE)
A61K38/395A61K31/661A61K31/683A61K31/685A61K31/688A61K33/14A61K38/1709
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,682,128
App. No.
14/741,883
Granted
Jun 20, 2017
Kind
B2
Abstract

An aqueous composition for application in a method for surgical or therapeutic treatment of the human or animal body or in a diagnostic procedure which is practiced on the human or animal body, the composition comprising osmotically active particles and containing less than 70 μl −1 of amniotic cells, the osmolarity of the composition being in the range from 240.0 mosm/l to less than 308.0 mosm/l, and the chloride ion concentration in the composition being not more than 130.0 mmol/l. An aqueous composition for application with an amniotic infusion, the composition containing less than 70 μl −1 of amniotic cells and comprising at least one surfactant, is also disclosed.

Claims (18)

1. An aqueous composition for application in amnioinfusion, wherein the composition contains fewer than 70 amniotic cells per μl and the composition contains at least one surfactant.

2. The composition as claimed in claim 1 , wherein the composition contains at least one phosphatidylcholine.

3. The composition as claimed in claim 2 , wherein a weight fraction of phosphatidylcholine, based on all lipids, is greater than 50.0% by weight.

4. The composition as claimed in claim 1 , wherein the composition contains sphingomyelin.

5. The composition as claimed in claim 4 , wherein the composition contains at least one phospholipid in a weight ratio of phospholipids to sphingomyelin greater than 1.5.

6. The composition as claimed in claim 1 , wherein the surfactant is a surfactant protein and a weight fraction of all surfactant proteins, based on the total weight of the composition, is greater than 1.0 mg/l.

7. The composition as claimed in claim 1 , wherein the composition contains at least one phospholipid and a weight fraction of all phospholipids, based on the total weight of the composition, is greater than 120.0 mg/l.

8. The composition as claimed in claim 1 , wherein the osmolarity of the composition is in the range from 240.0 mosm/l to 300.0 mosm/l.

9. The composition as claimed in claim 1 , wherein the composition contains a calcium ion and a calcium ion concentration in the composition is in the range from 1.0 mmol/l to 2.5 mmol/l.

10. A combination comprising the individual components of a composition as claimed in claim 1 in at least two different fractions.

11. A method for performing amnioinfusion, the method comprising infusing the aqueous composition according to claim 1 into an amniotic cavity of a human or an animal patient.

12. A method for performing amnioinfusion, the method comprising infusing the aqueous composition according to claim 1 into an amniotic cavity of a human or an animal patient to maintain a normal fluid volume in the amniotic cavity of the patient.

13. A method for performing amnioinfusion, the method comprising continuously infusing the aqueous composition according to claim 1 into an amniotic cavity of a human or an animal patient.

14. A method for performing amnioinfusion, the method comprising continuously infusing the aqueous composition according to claim 1 into an amniotic cavity of a human or an animal patient for a period of at least 30 minutes.

15. A method for performing amnioinfusion, the method comprising infusing the aqueous composition according to claim 1 into an amniotic cavity of a pregnant human or a pregnant animal patient to treat preterm premature rupture of membranes in the patient.

16. The method of claim 15 , wherein the patient is a human patient between week 13 of pregnancy and week 40 of pregnancy.

17. A method for performing amnioinfusion, the method comprising infusing the aqueous composition according to claim 1 into an amniotic cavity of a pregnant human or a pregnant animal patient to expedite lung maturation of a fetus in the pregnant patient.

18. A method for treating a patient, the method comprising rinsing a body cavity or region of a human or an animal patient with the aqueous composition according to claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2019
From: TCHIRIKOV, MICHAEL
To: PRENATAL INTERNATIONAL GMBH
Reel/Frame 048569/0223 →
Priority Claims (1)
EP 11000044 · Jan 5, 2011 · regional
Continuity (2)
Continuation 13978052
Related Publication 20150343027A1 · Dec 3, 2015